Skip to content

Efficacy of platelet-rich plasma (PRP) in preventing post-surgical scar from endoscopic frontal sinusotomy

Efficacy of platelet-rich plasma (PRP) in preventing post-surgical scar from endoscopic frontal sinusotomy

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20241023002
Enrollment
30
Registered
2024-10-23
Start date
2022-07-04
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with chronic rhinosinusitis with or without nasal polyp (CRSwNP &amp

Interventions

Platelet-rich plasma (PRP) obtained from peripheral blood sample was centrifuged with 1,250 and 3,000 rpms, 5 minutes for each speed. Then the PRP soaked absorbable hemostat was applied at frontal sin
PRP application,Control

Sponsors

Navamindradhiraj University Research Fund
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1) patients aged between 18 and 60 years old with chronic rhinosinusitis and underwent bilateral endoscopic sinus surgery 2) Bilateral frontal sinusitis (with Lund Mackay score equal or greater than 1 on both sides). 3) Undergone the same frontal sinus operation including Draf IIa or Draf IIb, 4) Using the same surgical techniques on both sides, and 5) the participants willing to participate in the study

Exclusion criteria

Exclusion criteria: 1)patients with hematologic disorders such as abnormal bleeding, platelet dysfunction, and thrombocytopenia (platelet count less than 100,000 per microliter). 2) Undergone previous surgeries of nasal cavity and paranasal sinuses. 3) Underlying conditions affecting treatment outcome such as uncontrolled diabetes mellitus, immunocompromised states, acute bacterial sinusitis and invasive fungal sinusitis. 4) patients with steroid-dependent condition. 5) patients with disorders of ciliary dysfunction, such as primary ciliary dyskinesia (PCD), cystic fibrosis (CF), and vasculitis (Wegener's granulomatosis and Churg-Strauss syndrome) 6) patients who were unable to comply with treatment protocol, and 7) patients who took anticoagulants.

Design outcomes

Primary

MeasureTime frame
frontal sinus ostial area On the 30th and 90th day post-operation calculated using area of ellipse by the width and length of frontal sinus ostium using frontal ostium seeker instrument,patency grading On the 30th and 90th day post-operation visual assessment grading from grade 0: patent, grade 1: re-stenosed or partially occluded, grade 2: occluded

Secondary

MeasureTime frame
Inflammation VAS scale On the 30th and 90th day post-operation Visual analog scale (0-100),Polypoid edema grading On the 30th and 90th day post-operation visual assessment grading, grade 0: normal mucosa, no visible polyp to grade 2: expanded amount of polypoid edema,Adhesion and scarring grading On the 30th and 90th day post-operation Visual assessment grading, grade 0: no visible granulation/scarring to grade 3: significant amount of scarring or contraction causing obstruction of the FSO requiring intervention ,Need for postoperative interventions On the 30th and 90th day post-operation including additional steroid prescription and revision frontal sinus surgery in postoperative period

Countries

Thailand

Contacts

Public ContactSuphakrit Limpornpugdee

Navamindradhiraj University

suphakrit.lim@nmu.ac.th022443395

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026